**Supplementary Materials**

****

**Fig. S1.** Individual macaqueplasma CAB concentrations at the time of challenge by study. Each data point denotes the CAB concentration an individual macaque dose with 50 mg/kg on week 0 and 4 (blue), 50 mg/kg on week 0 (red) or 25 mg/kg on week 0 and 50 mg/kg on week 4 (green). Closed symbols represent aviremic macaques while open symbols represent macaques that became viremic. The solid line represents the mean of each group. The dashed horizontal line represents 4x PAIC90.

****

**Fig. S2.** Kaplan-Meier plots and mean pharmacokinetics summarizing the evaluation of CAB LA as PrEP against parenteral transmission.(A)Overlay of Kaplan-Meier plots from SIVmac251 intravenous challenge experiments evaluating CAB LA as PrEP. (B) Mean plasma CAB concentration from three experiments evaluating CAB LA as PrEP against SIVmac251 in macaques. Error bars represent standard deviation. Legend in (A) for both panels.

|  |  |  |  |
| --- | --- | --- | --- |
| **Study** | **Animal ID** | **Time point (weeks)** | **Sequence/Mutations** |
| 50 mg/kg; 50 mg/kg | IB13 | 9 | I191M |
| 10 | I191M |
| 11 | I191M |
| 12 | I191M |
| 13 | I191M |
| 15 | I191M |
| 16 | I191M |
| 25 mg/kg; 50 mg/kg | EL75 | 7 | V110I |
| 8 | V110I |
| 9 | V110I, D232N |
| 17 | V110I, D232N, A248T |
| 19 | V110I, D232N, A248T |
| 22 | V110I, D232N, A248T |
| 25 mg/kg; 50 mg/kg | FB90 | 15 | Wild type |
| 16 | I210V |
| 19 | Wild type |
| 20 | Wild type |

**Table S1.** Summary of SIV integrase coding region from plasma virus of infected CAB LA-treated macaques.